gdc-0973 has been researched along with Pituitary-Neoplasms* in 2 studies
1 trial(s) available for gdc-0973 and Pituitary-Neoplasms
Article | Year |
---|---|
BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry. Eligible patients who had papillary craniopharyngiomas that tested positive for. Of the 16 patients in the study, 15 (94%; 95% confidence interval [CI], 70 to 100) had a durable objective partial response or better to therapy. The median reduction in the volume of the tumor was 91% (range, 68 to 99). The median follow-up was 22 months (95% CI, 19 to 30) and the median number of treatment cycles was 8. Progression-free survival was 87% (95% CI, 57 to 98) at 12 months and 58% (95% CI, 10 to 89) at 24 months. Three patients had disease progression during follow-up after therapy had been discontinued; none have died. The sole patient who did not have a response stopped treatment after 8 days owing to toxic effects. Grade 3 adverse events that were at least possibly related to treatment occurred in 12 patients, including rash in 6 patients. In 2 patients, grade 4 adverse events (hyperglycemia in 1 patient and increased creatine kinase levels in 1 patient) were reported; 3 patients discontinued treatment owing to adverse events.. In this small, single-group study involving patients with papillary craniopharyngiomas, 15 of 16 patients had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT03224767.). Topics: Antineoplastic Agents; Craniopharyngioma; Disease Progression; Humans; Mitogen-Activated Protein Kinase Kinases; Pituitary Neoplasms; Proto-Oncogene Proteins B-raf; Remission Induction; Vemurafenib | 2023 |
1 other study(ies) available for gdc-0973 and Pituitary-Neoplasms
Article | Year |
---|---|
En Face Widefield OCT Angiography of MEK Inhibitor-Associated Retinopathy.
Topics: Azetidines; Craniopharyngioma; Female; Fluorescein Angiography; Fundus Oculi; Humans; MAP Kinase Kinase 1; Middle Aged; Piperidines; Pituitary Neoplasms; Protein Kinase Inhibitors; Retinal Diseases; Tomography, Optical Coherence; Vemurafenib | 2021 |